Insider Buying: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Director Purchases 417,646 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Director Arjun Goyal purchased 417,646 shares of the company’s stock in a transaction on Friday, May 16th. The stock was purchased at an average cost of $12.73 per share, for a total transaction of $5,316,633.58. Following the purchase, the director now directly owns 462,585 shares in the company, valued at approximately $5,888,707.05. This trade represents a 929.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Arjun Goyal also recently made the following trade(s):

• On Thursday, May 15th, Arjun Goyal acquired 44,939 shares of Centessa Pharmaceuticals stock. The stock was acquired at an average price of $12.24 per share, for a total transaction of $550,053.36.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $12.82 on Thursday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average price is $13.22 and its two-hundred day moving average price is $15.52. The company has a market cap of $1.71 billion, a PE ratio of -8.38 and a beta of 1.53. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.15. On average, analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on CNTA shares. Guggenheim reiterated a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Piper Sandler started coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They issued an “overweight” rating and a $38.00 target price on the stock. Oppenheimer began coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set an “outperform” rating and a $6.00 target price on the stock. Chardan Capital began coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $27.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in shares of Centessa Pharmaceuticals in the first quarter valued at approximately $2,176,000. Exome Asset Management LLC lifted its holdings in Centessa Pharmaceuticals by 3.7% during the 1st quarter. Exome Asset Management LLC now owns 142,744 shares of the company’s stock worth $2,053,000 after purchasing an additional 5,028 shares during the last quarter. Millennium Management LLC boosted its stake in Centessa Pharmaceuticals by 52.9% in the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock valued at $8,760,000 after purchasing an additional 210,737 shares during the period. Cutter Capital Management LP grew its holdings in Centessa Pharmaceuticals by 184.3% in the 1st quarter. Cutter Capital Management LP now owns 418,127 shares of the company’s stock valued at $6,013,000 after buying an additional 271,051 shares in the last quarter. Finally, Allostery Investments LP increased its position in Centessa Pharmaceuticals by 34.4% during the 1st quarter. Allostery Investments LP now owns 382,524 shares of the company’s stock worth $5,501,000 after buying an additional 98,007 shares during the period. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.